Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

Overview

The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA) use disorder.

Full Title of Study: “CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2015

Detailed Description

Stage 1 will include 20 individuals with severe stimulant use disorder (methamphetamine type) enrolled across three study sites. Following a maximum 30-day screening period to establish eligibility, participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks. Take-home oral study medication (BRP) will be dispensed weekly for dosing on non-clinic days. Participants will be asked to attend clinic twice weekly for observed BRP dosing, collection of urine samples, assessments, and medical management. Following the 8-week active medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visit during Week 9. If Stage 1 data document success (see criteria below) in at least 3 "responder" study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants. Using the same criteria of "responder" success, if the combined stages document success in at least 9 of 49 study participants, the combination medication will be considered to have shown sufficient potential to advance to a large-scale placebo-controlled trial.

Interventions

  • Drug: naltrexone plus bupropion
    • Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.

Arms, Groups and Cohorts

  • Experimental: naltrexone plus bupropion
    • extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)

Clinical Trial Outcome Measures

Primary Measures

  • Participants Categorized as “Responders”
    • Time Frame: Weeks 4-8
    • Study “Responders” were defined as participants providing six MA-negative urine tests of eight administered in the evaluation period (the last four weeks of the active medication phase), including the last test collected in the final study week of the active medication phase.

Participating in This Clinical Trial

Inclusion Criteria

  • Be 18 to 65 years of age; – Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study; – Demonstrate understanding of study procedures by correctly answering all questions on the consent competency tool; – Be interested in reducing or stopping methamphetamine use; – Meet DSM-5 criteria for severe methamphetamine use disorder; – Meet subjective and objective methamphetamine use criteria as defined by the protocol; – Meet subjective and objective measures of being opioid-free prior to enrollment and medication induction per study medical clinician's determination (including passing a naloxone challenge); – Agree to use study cellphone to record videos of take-home dosing for transfer to study team. – If female of childbearing potential, agree to use acceptable birth control methods during participation in the study; Exclusion Criteria:

  • Have known allergy or sensitivity to study medications; – Have a medical history or condition that would make study participation difficult or unsafe; – Have an acute psychiatric disorder or condition that would make study participation difficult or unsafe; – Liver function test results greater than 5 times the upper limit of normal or other exclusionary clinical lab test values; – Recent or ongoing treatment with medications that, in the judgment of the study medical clinician, could interact adversely with study drugs or interfere with study participation; – Have a current pattern of alcohol, benzodiazepine, or other sedative-hypnotic use, as determined by the study medical clinician, which would preclude safe participation; – Pending action or situation that might prevent remaining in the area for the duration of the study or prevent participation in study activities – Be currently pregnant or breastfeeding;

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Walter Ling
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Walter Ling, Professor of Psychiatry and Director, UCLA Integrated Substance Abuse Programs – University of California, Los Angeles
  • Overall Official(s)
    • Walter Ling, M.D., Principal Investigator, UCLA Integrated Substance Abuse Programs
    • Larissa Mooney, M.D., Principal Investigator, UCLA Integrated Substance Abuse Programs

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.